[Effectiveness of combined treatment in patient with advanced ovarian carcinoma].
The objectives of this study was to evaluate chemotherapy, GnRH analogues and radiotherapy as adjuvant treatment in advanced epithelial ovarian carcinoma. It was a retrospective analysis. 69 patients with stage III and IV epithelial ovarian carcinoma after maximal debulking surgery received adjuvant chemotherapy with cyclophosphamide and cisplatin or carboplatin (6-9 course). Additionally some of them were treated with radiotherapy or/and GnRH agonists. In relation to treatment patients were divided into 4 groups: I--received chemotherapy + GnRH agonist + radiotherapy, II--chemotherapy + GnRH agonist, III--chemotherapy + radiotherapy and IV--chemotherapy. Statistical analysis was based on nonparametric U-Mann-Whitney test. Survival analysis performed with Kaplan-Meyer method. We found statistical differences in overall survival, 5-years survival and overall complete response rate between the group treated with only chemotherapy and groups the also received radiotherapy or/and GnRH analogues. Combination treatment in advanced epithelial ovarian cancer seems to be a reasonable way of therapeutic management. Radiotherapy and GnRH agonists with chemotherapy are effective consolidation therapy for stage III and IV ovarian cancer.